Novartis receives approval in the European Union for Onbrez Breezhaler, a new once-daily bronchodilator for patients with COPD
Links shared publicly online about this topic.
- 1,558total visits
Novartis receives approval in the European Union for Onbrez Breezhaler, a new once-daily bronchodilator for patients with COPD
Basel, December 3, 2009 - Novartis announced today that the European Commission (EC) has approved Onbrez Breezhaler (QAB149 or indacaterol) in both 150 mcg and 300 mcg doses as a new once-daily maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).
View full resource at novartis.com
Tags: COPD, Disease and Condition, Novartis, Pulmonology
Most Recently Shared on December 3, 2009 at 1:40 pm By:
Novartis gets EU approval for new COPD treatment - http://ow.ly/Ias3
Advertisement
